HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daisaku Masuda Selected Research

Probucol (Lorelco)

6/2022Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT.
7/2021Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
2/2021Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
6/2016Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
8/2015Did we abandon probucol too soon?
1/2012Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
11/2005Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Daisaku Masuda Research Topics

Disease

14Dyslipidemias (Dyslipidemia)
09/2021 - 05/2009
13Coronary Artery Disease (Coronary Atherosclerosis)
08/2022 - 06/2007
13Cardiovascular Diseases (Cardiovascular Disease)
08/2022 - 10/2007
13Atherosclerosis
10/2019 - 11/2005
11Hypertriglyceridemia
11/2020 - 05/2009
9Hyperlipidemias (Hyperlipidemia)
11/2020 - 04/2008
8Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
08/2022 - 01/2012
7Xanthomatosis (Xanthoma)
06/2022 - 11/2005
6Coronary Disease (Coronary Heart Disease)
02/2021 - 12/2009
6Type 2 Diabetes Mellitus (MODY)
11/2020 - 05/2016
4Inflammation (Inflammations)
10/2019 - 01/2012
4Metabolic Syndrome (Dysmetabolic Syndrome X)
02/2017 - 09/2010
3Hypertension (High Blood Pressure)
05/2022 - 05/2009
3Fibrosis (Cirrhosis)
10/2019 - 01/2013
3Cardiomyopathies (Cardiomyopathy)
10/2019 - 01/2013
3Tangier Disease
10/2018 - 06/2007
3Body Weight (Weight, Body)
02/2018 - 01/2015
3Hypothyroidism
02/2017 - 11/2009
3Insulin Resistance
01/2015 - 04/2012
3Platelet Glycoprotein IV Deficiency
01/2012 - 05/2009
2Carotid Artery Diseases
06/2022 - 11/2005
2Pancreatitis
09/2021 - 11/2020
2Cardiomegaly (Heart Hypertrophy)
01/2020 - 01/2019
2Metabolic Diseases (Metabolic Disease)
01/2020 - 05/2019
2Heart Failure
10/2019 - 01/2013
2Myocardial Infarction
10/2019 - 01/2013
2Cholesteryl Ester Transfer Protein Deficiency
03/2019 - 01/2018
2Hyperglycemia
06/2018 - 05/2009
2Hyperlipoproteinemia Type III (Broad Beta Disease)
02/2017 - 12/2009
2Coronary Stenosis (Coronary Artery Stenosis)
02/2017 - 09/2012
2Chronic Renal Insufficiency
02/2017 - 09/2010
2Obesity
02/2017 - 09/2010
2Hyperthyroidism
01/2012 - 11/2009
2Thyroid Diseases (Thyroid Disease)
01/2012 - 11/2009
2ST Elevation Myocardial Infarction
01/2011 - 05/2010
1Diabetes Mellitus
12/2022
1Inborn Genetic Diseases (Disease, Hereditary)
05/2022
1Failure to Thrive
09/2021
1Abdominal Pain (Pain, Abdominal)
09/2021
1Liver Diseases (Liver Disease)
01/2020
1Hypoxia (Hypoxemia)
10/2019
1Coronary Occlusion
10/2019

Drug/Important Bio-Agent (IBA)

14Lipoproteins (Lipoprotein)IBA
08/2022 - 05/2009
13oxidized low density lipoproteinIBA
06/2022 - 12/2009
12HDL CholesterolIBA
05/2022 - 11/2005
11Apolipoprotein B-48IBA
02/2017 - 11/2009
10LipidsIBA
08/2022 - 05/2015
9Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2022 - 09/2010
9LDL CholesterolIBA
06/2022 - 09/2010
8HDL LipoproteinsIBA
02/2021 - 06/2007
7Probucol (Lorelco)FDA Link
06/2022 - 11/2005
7Triglycerides (Triacylglycerol)IBA
11/2020 - 05/2009
7CholesterolIBA
02/2017 - 07/2007
6(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
09/2021 - 02/2018
6ChylomicronsIBA
02/2017 - 11/2009
5Chylomicron RemnantsIBA
02/2017 - 05/2009
4LDL Lipoproteins (beta Lipoproteins)IBA
06/2022 - 09/2010
4Pharmaceutical PreparationsIBA
05/2022 - 08/2015
4Ezetimibe (Zetia)FDA Link
02/2017 - 09/2010
4AdiponectinIBA
01/2015 - 07/2007
3ApolipoproteinsIBA
08/2022 - 09/2012
3Fibric Acids (Fibrates)IBA
01/2020 - 02/2017
3Glucose (Dextrose)FDA LinkGeneric
01/2019 - 09/2012
3Niacin (Nicotinic Acid)FDA LinkGeneric
05/2015 - 04/2012
3Apolipoprotein A-I (Apolipoprotein A1)IBA
10/2008 - 07/2007
2AntioxidantsIBA
02/2021 - 01/2012
2Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2020 - 02/2017
2ProgranulinsIBA
01/2020 - 10/2013
2Complement System Proteins (Complement)IBA
01/2020 - 03/2019
2Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2020 - 02/2017
2Cholesterol Ester Transfer ProteinsIBA
03/2019 - 01/2018
2Proteins (Proteins, Gene)FDA Link
03/2019 - 10/2013
2Adenosine Triphosphate (ATP)IBA
01/2019 - 09/2010
2Dipeptidyl-Peptidase IV InhibitorsIBA
06/2018 - 02/2017
2Fenofibrate (CiL)FDA LinkGeneric
02/2018 - 06/2010
2DiglyceridesIBA
02/2017 - 04/2012
2MK-0524IBA
05/2015 - 01/2015
2Thyroid HormonesIBA
01/2012 - 11/2009
2hydroxide ionIBA
01/2012 - 11/2009
2Hypolipidemic Agents (Antihyperlipidemics)IBA
01/2012 - 11/2005
2ATP-Binding Cassette Transporters (ABC Transporters)IBA
09/2010 - 06/2009
1Lipoprotein(a)IBA
08/2022
1Dietary Fats (Dietary Fat)IBA
09/2021
1TabletsIBA
11/2020
1Hemoglobins (Hemoglobin)IBA
11/2020
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
11/2020
1evolocumabIBA
11/2020
1Nicotinic AcidsIBA
01/2020
1CateninsIBA
01/2020
1Oxidoreductases (Dehydrogenase)IBA
01/2020
1Coenzyme A (CoA)IBA
01/2020
1CreatinineIBA
01/2020
1EstersIBA
01/2020
1CoagulantsIBA
10/2019
1Proteinase-Activated ReceptorsIBA
10/2019
1RivaroxabanIBA
10/2019

Therapy/Procedure

5Therapeutics
02/2021 - 09/2010
3Secondary Prevention
02/2021 - 08/2015
2Ligation
10/2019 - 01/2013
2Percutaneous Coronary Intervention
01/2011 - 09/2010